As of November 7, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Palvella Therapeutics Inc. The largest reported stake is Jennison Associates LLC's, at 7.7%. 13 filings are on record since August 14, 2025 (Schedule 13G/A, October 28, 2026).
Sell to companies like Palvella Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Jennison Associates LLC · Sole voting: 1,101,652 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 1,101,652 · SCHEDULE 13G/A, 2026-10-28
- · Reporting person: First Light Asset Management, LLC · Sole voting: 0 · Shared voting: 769,117 · Sole dispositive: 0 · Shared dispositive: 769,117 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Biotechnology Value Fund L P · Sole voting: 0 · Shared voting: 352,699 · Sole dispositive: 0 · Shared dispositive: 352,699 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Prudential Financial Inc · Sole voting: 0 · Shared voting: 826,531 · Sole dispositive: 0 · Shared dispositive: 962,374 · SCHEDULE 13G, 2026-08-10
- · Holder: Jennison Associates LLC · Percent: 6.7% · SCHEDULE 13G
Palvella Therapeutics Inc has 13 Schedule 13D or 13G filings on record since 2025-08-14. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Jennison Associates LLC | 7.7% | 1,101,652 | SCHEDULE 13G/A, 2026-10-28 | 2026-09-30 |
| Suvretta Capital Management, LLC | 7.4% | 822,400 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
| Prudential Financial Inc | 6.7% | 962,374 | SCHEDULE 13G, 2026-08-10 | 2026-06-30 |
| Frazier Life Sciences Public Fund, L.P. | 6% | 706,360 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| BlackRock, Inc. | 5.7% | 812,953 | SCHEDULE 13G, 2026-07-29 | 2026-06-30 |
| First Light Asset Management, LLC | 5.34% | 769,117 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Bvf Partners L P | 4.7% | 672,789 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Samsara BioCapital, L.P. | 3.1% | 339,743 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
Holding shares or following this stake? See who's behind Palvella Therapeutics Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Palvella Therapeutics Inc and the records around it.
Palvella Therapeutics Inc elsewhere on the record
- Leadership changes Jun 2026
- Who owns it
Companies that share a holder
- First Light Asset Management, LLC also filed stake reports on 12 other companies: NeuroPace Inc (Sep 2026), Neogenomics, Inc. (Aug 2026), TriSalus Life Sciences, Inc. (Jul 2026)
- Jennison Associates LLC also filed stake reports on 14 other companies: LENDINGTREE INC (Oct 2026), REZOLUTE INC (Oct 2026), NEUROGENE INC (Oct 2026)
- Samsara BioCapital, L.P. also filed stake reports on 14 other companies: PMV Pharmaceuticals, Inc. (Sep 2026), Eloxx Pharmaceuticals, Inc. (Aug 2026), RANI THERAPEUTICS HOLDINGS, INC. (May 2026)
Watch Palvella Therapeutics Inc
Get an email when Palvella Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Palvella Therapeutics Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Palvella Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Palvella Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Jennison Associates LLC | 1,101,652 | 0 | 0 | 1,101,652 | SCHEDULE 13G/A, 2026-10-28 |
| Prudential Financial Inc | 0 | 826,531 | 0 | 962,374 | SCHEDULE 13G, 2026-08-10 |
| BlackRock, Inc. | 796,317 | 0 | 812,953 | 0 | SCHEDULE 13G, 2026-07-29 |
| First Light Asset Management, LLC | 0 | 769,117 | 0 | 769,117 | SCHEDULE 13G/A, 2026-08-14 |
| Mathew P. Arens | 0 | 769,117 | 0 | 769,117 | SCHEDULE 13G/A, 2026-08-14 |
| Biotechnology Value Fund L P | 0 | 352,699 | 0 | 352,699 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf I Gp LLC | 0 | 352,699 | 0 | 352,699 | SCHEDULE 13G/A, 2026-08-14 |
| Biotechnology Value Fund Ii LP | 0 | 265,660 | 0 | 265,660 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Ii Gp LLC | 0 | 265,660 | 0 | 265,660 | SCHEDULE 13G/A, 2026-08-14 |
| Biotechnology Value Trading Fund OS LP | 0 | 44,510 | 0 | 44,510 | SCHEDULE 13G/A, 2026-08-14 |
| BVF Partners OS Ltd. | 0 | 44,510 | 0 | 44,510 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Gp Holdings LLC | 0 | 618,359 | 0 | 618,359 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Partners L P | 0 | 672,789 | 0 | 672,789 | SCHEDULE 13G/A, 2026-08-14 |
| Bvf Inc | 0 | 672,789 | 0 | 672,789 | SCHEDULE 13G/A, 2026-08-14 |
| Lampert Mark N | 0 | 672,789 | 0 | 672,789 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Palvella Therapeutics Inc by CUSIP 697947109 and gives its principal executive office as 353 W. Lancaster Avenue, Suite 200, Wayne, PA 19087 (SCHEDULE 13G/A, 2026-10-28).
What the percentages are based on
The following percentages are based on 14,342,844 Shares outstanding as of May 1, 2026, which is the total number of Shares outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 7, 2026.Bvf Partners L P, SCHEDULE 13G/A, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Frazier Life Sciences Public Fund, L.P. | 4.9% | SCHEDULE 13G/A |
| 2025-08-14 | Samsara BioCapital, L.P. | 3.1% | SCHEDULE 13G/A |
| 2025-11-13 | Suvretta Capital Management, LLC | 7.4% | SCHEDULE 13G/A |
| 2025-11-14 | Bvf Partners L P | 9.99% | SCHEDULE 13G/A |
| 2026-02-13 | Frazier Life Sciences Public Fund, L.P. | 6% | SCHEDULE 13G/A |
| 2026-02-17 | Bvf Partners L P | 7.1% | SCHEDULE 13G/A |
| 2026-02-17 | First Light Asset Management, LLC | 7.49% | SCHEDULE 13G |
| 2026-07-29 | BlackRock, Inc. | 5.7% | SCHEDULE 13G |
| 2026-08-03 | Jennison Associates LLC | 6.7% | SCHEDULE 13G |
| 2026-08-10 | Prudential Financial Inc | 6.7% | SCHEDULE 13G |
| 2026-08-14 | Bvf Partners L P | 4.7% | SCHEDULE 13G/A |
| 2026-08-14 | First Light Asset Management, LLC | 5.34% | SCHEDULE 13G/A |
| 2026-10-28 | Jennison Associates LLC | 7.7% | SCHEDULE 13G/A |
Questions about who owns Palvella Therapeutics Inc
Who owns Palvella Therapeutics Inc?
On this page, 6 holders' latest ownership filings report 5% or more of Palvella Therapeutics Inc: Jennison Associates LLC (7.7%, Schedule 13G/A, filed 2026-10-28), Suvretta Capital Management, LLC (7.4%, Schedule 13G/A, filed 2025-11-13), Prudential Financial Inc (6.7%, Schedule 13G, filed 2026-08-10), Frazier Life Sciences Public Fund, L.P. (6%, Schedule 13G/A, filed 2026-02-13) and BlackRock, Inc. (5.7%, Schedule 13G, filed 2026-07-29); 1 more is listed above.
Who are the largest shareholders of Palvella Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Palvella Therapeutics Inc on this page are Jennison Associates LLC (7.7%), Suvretta Capital Management, LLC (7.4%) and Prudential Financial Inc (6.7%).
When did Jennison Associates LLC buy into Palvella Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Jennison Associates LLC on this page is the Schedule 13G, filed 2026-08-03, reporting 6.7%; its latest, Schedule 13G/A filed 2026-10-28, reports 7.7%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Palvella Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 30, 2026 | Leadership change: Matthew Pauls appointed, Director | — | Leadership changes | Source |
| April 13, 2026 | Leadership change: John Doux appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Palvella Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.